Enterprise Development

2016

  • 2016-03  Company established

2017

  • 2017 Research and Production Center for Cell Therapy Products established in Shanghai Thousand Talents Plan Entrepreneurship Park

2019

  • 2019-03  ISO9001:2015 Quality Management System certified

2020

  • 2020-06  Inspection Report obtained from National Institute for Food and Drug Control (China)

2021

  • 2021-10  Kick off meeting of clinical research project with Sichuan Provincial People's Hospital (Liver cirrhosis)

  • 2021-12  Intellectual Property Management System certified

2022

  • 2022-05 1st IND approval (Indication: Acute Respiratory Distress Syndrome, ARDS)

  • 2022-05 2nd IND approval (Indication: Ankylosing Spondylitis, AS)

  • 2022-09 3rd IND approval (Indication: Burn)

  • 2022-12 4th IND approval (Indication: Liver Cirrhosis)

2023

  • 2023-04  1st ARDS patient enrolled

  • 2023-06  4000m² pilot plant completed in Shanghai

  • 2023-04  1st liver cirrhosis patient enrolled

  • 2023-12  All ankylosing spondylitis patients enrolled in Phase I clinical trial